On April 26, 2017, the Supreme Court heard oral argument in Sandoz Inc. v. Amgen Inc. on two questions regarding the Biologics Price Competition and Innovation Act (“BPCIA”): (1) whether a biosimilar applicant’s 180 days’ notice of commercial marketing is properly given only after its biosimilar product has been approved by the FDA, and (2) whether a biosimilar applicant is obligated to provide its abbreviated biologics license application (“aBLA”) and manufacturing information to the reference product sponsor within 20 days after the FDA accepts the aBLA for filing, thereby triggering early patent litigation.

Download PDF

Brendan O’Malley has extensive litigation and client counseling experience in technology areas including therapeutic monoclonal antibodies and antibody expression systems, transgenic mice, non-insulin peptide treatments for diabetes, and DNA sequencing. Brendan’s Ph.D. research at Tufts University School of Medicine focused on protein-protein interactions in hepatitis B and hepatitis D virion assembly.